Cam duvar boyunca enjekte edin
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
Eli Lilly plans to submit the NDA in Q4 2026, followed by a 610 month FDA review
Some clinicians introduce BPC-157 specifically to support GI comfort during GLP-1 dose escalation
He has tested knock-off brands and found them to be lacking and the percentage to be incorrectly stated for marketing purposes
Mounjaro is a subcutaneous injection prescribed to manage blood sugar levels in adults with type 2 diabetes